中外製薬、Genedata Expressionistの利用拡大：
個別化医療へ向けたゲノムデータ解析

Japan’s leading pharmaceutical company for oncological therapies expands use of Genedata Expressionist

March 26, 2012
Basel, Switzerland and Tokyo, Japan

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Chugai Pharmaceutical Company extended its multi-year licensing agreement of Genedata Expressionist^® software. One of Japan’s leading pharmaceutical companies and a member of the Roche Group, Chugai develops therapeutic drugs in the fields of oncology, diabetes, and other chronic diseases. Chugai uses Genedata Expressionist to streamline R&D processes and for enterprise-wide analysis and management of microarray data. Moving forward, the company will expand its use of Genedata Expressionist for analysis of genomic data for personalized medicine.

“Over the years, the Genedata Expressionist solution has been instrumental in helping standardize our workflows for microarray data analysis,” noted Mr. Junichi Muroya of Chugai’s bioinformatics department. “The ability to have one platform on which we can manage, analyze, and visualize massive amounts of raw data—typically a few thousand data sets at once—has greatly increased our processing speed and enabled sophisticated statistical analysis. Our successful history with Genedata holds much promise for the future. We will continue to rely on Genedata Expressionist for our day-to-day analysis projects and explore its use for next-generation sequencing.”

Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size.  Genedata Expressionist analyzes and manages genomic, transcriptomic, and epigenomic data from leading technologies spanning next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. In addition, Genedata Expressionist enables integrated analysis and management of all major molecular profiling applications by including a comprehensive solution for proteomic, metabolomic, and lipidomic data from all major mass spectrometry technologies.

“Chugai leads the way in drug discovery to combat chronic illnesses and we are deeply gratified by Chugai’s decision to move forward with Genedata Expressionist,” said Dr. Othmar Pfannes, CEO of Genedata. “Our continued support of Chugai’s bioinformatics projects underscores the value of our software, validates the strength of our partnership, and highlights our dedication to the Japan market.”